Alivus Life Sciences Ltd (ALIVUS) Q4FY25 Concall Summary - Mar-2025 Qtr
Performance Overview
- Glenmark Life Sciences reported strong Q4 results with revenue of Rs. 650 crores, a 21.1% YoY growth.
- Growth was broad-based across all regions and business segments (GPL and non-GPL).
- EBITDA margin for Q4 was 32.1%, a significant increase of 520 bps YoY and 80 bps QoQ, driven by favorable product mix and new product launches.
- FY25 revenue reached Rs. 2387 crores, a 4.5% YoY growth, meeting guidance.
- Margins were maintained at 30% YoY despite the absence of PLI benefits.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.